Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

26.1%

85 terminated/withdrawn out of 326 trials

Success Rate

67.9%

-18.6% vs industry average

Late-Stage Pipeline

6 trials in Phase 3/4

Results Transparency

71%

128 of 180 completed trials have results

Key Signals

38 recruiting128 with results65 terminated20 withdrawn

Enrollment Performance

Analytics

Phase 2

138(48.4%)

N/A

72(25.3%)

Phase 1

58(20.4%)

Early Phase 1

11(3.9%)

Phase 4

3(1.1%)

Phase 3

3(1.1%)

285Total

Phase 2(138)

N/A(72)

Phase 1(58)

Early Phase 1(11)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (326)

Showing 20 of 326 trials

NCT07132645Early Phase 1Recruiting

An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer

Role: lead

NCT07121595Phase 2Recruiting

Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial

Role: lead

NCT04518748Phase 1Active Not Recruiting

Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.

Role: lead

NCT01973881Recruiting

Quantitative MRI for Myelofibrosis

Role: lead

NCT06866262Phase 1Recruiting

Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial

Role: lead

NCT03099356Phase 2Recruiting

Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

Role: lead

NCT07737769Phase 1Not Yet Recruiting

Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome

Role: lead

NCT06580054Phase 2Active Not Recruiting

Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma

Role: lead

NCT04140162Phase 2Active Not Recruiting

Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

Role: lead

NCT05911269Not ApplicableCompleted

Feasibility of Virtual, Tailored, Music-Based Relaxation for Anxiety in Adolescent and Young Adult Cancer Survivors

Role: lead

NCT07096999Recruiting

SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy

Role: lead

NCT06784336Phase 2Recruiting

Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation

Role: lead

NCT01750567Phase 2Completed

A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL

Role: lead

NCT07673614Not ApplicableNot Yet Recruiting

Transcranial Direct Current Stimulation for the Treatment of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors

Role: lead

NCT06356155Phase 2Recruiting

Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial Cancer

Role: lead

NCT07532525Phase 1Recruiting

Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma

Role: lead

NCT06941324Not ApplicableRecruiting

Solution-Focused Brief Therapy for Support of Psychological Distress in Adolescent and Young Adult Cancer Survivors

Role: lead

NCT05996107Phase 1Recruiting

Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer

Role: lead

NCT04748042Phase 2Active Not Recruiting

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

Role: lead

NCT03781986Phase 1Active Not Recruiting

APG-115 in Salivary Gland Cancer Trial

Role: lead